Abstract
Objectives
Study design
Results
Conclusion
Implications
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionReferences
- Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone.4th ed. World Health Organization, Geneva2010
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998;57:315-324.
- Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the health of Young Women.Eur J Contracept Reprod Health Care. 1999; 4: 67-73
- Risk of idiopathic venous thromboembolism in users of progestogens alone.Lancet. 1999; 354: 1610-1611
- Progestin-only oral contraception: a comprehensive review.Contraception. 1994; 50: S9-195
- A comparison of the inhibition of ovulation achieved by desogestrel 75 µg and levonorgestrel 30 µg daily.Hum Reprod. 1999; 14: 982-985
Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 µg/day or levonorgestrel 30 µg/day. Eur J Contracept Reprod Health Care 1998;3:169-178.
- Bleeding problems and progestogen-only contraception.J Fam Plann Reprod Health Care. 2002; 28: 178-181
Grimes DA, Lopez LM, O’Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2013;11:CD007541.
- A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen.Eur J Contracept Reprod Health Care. 2015; 20: 419-427
- Drospirenone-only contraceptive: results from a multicentre comparative trial of efficacy, safety and tolerability.Contraception. 2015; 92: 439-444
- The preclinical biology of a new potent and selective progestin: trimegestone.Steroids. 2003; 68: 915-920
- Preclinical and clinical properties of trimegestone: a potent and selective progestin.Gynecol Endocrinol. 2007; 23: 310-319
- Ultrasound evaluation of ovarian activity under oral contraceptives.Contraception. 1993; 47: 583-590
- Hormonal effects of the 300 µg norethisterone (NET) minipill. 1. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration.Contraception. 1980; 21: 87-113
- Hormone treatment of endometriosis: the estrogen threshold hypothesis.Am J Obstet Gynecol. 1992; 166: 740-745
- Integrated pharmacometrics and systems pharmacology model-based analysis to guide GnRH receptor modulator development for management of endometriosis.CPT Pharmacometrics Syst Pharmacol. 2012 Oct; 17e11
Hadji P, Colli E, Regidor P-A. Bone health in estrogen-free contraception. Osteoporos Int 2019. Published online: https://doi.org/10.1007/s00198-019-05103-6.
Article info
Publication history
Footnotes
☆Financial support for the conduct of the study and preparation of the article was provided by Evestra GmbH. The sponsor was involved in the study design; in the analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
☆☆Conflict of interest: ID and CK are directors of dinox consultancy, CK is director and CD is employee of dinox GmbH, contract research organizations that received funding from Evestra GmbH for consultancy services, medical writing and conduct of the study, respectively. BS is managing director and AD is employee of SocraTec R&D, a CRO that received funding from Evestra GmbH for monitoring, data management and evaluation. MF is employee and KN is director of Evestra GmbH, a company developing the TMG ring.
